Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

Head Lice Clinical Trial

Official title:

A Double-Blind Randomized Study to Compare the Safety, Local Tolerability and Efficacy of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00994422
• Other study ID #: TOP010
• Status: Completed
• Phase: Phase 2
• First received: October 9, 2009
• Last updated: April 4, 2012
• Start date: October 2009
• Est. completion date: December 2009

Study information

• Verified date: April 2012
• Source: Topaz Pharmaceuticals Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the safety and efficacy of a 0.5% ivermectin cream to a placebo in subjects infested with head lice when used in an "at home" environment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 264
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• Subject must have an active head lice infestation defined as: At least 1 live louse (adult and/or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self-assess as being lice free).

• Subject is male or female.

• Subject weighs at least 15kg (33 lbs).

• Subject is in good general health based on medical history.

• Each subject must have an appropriately signed Informed Consent agreement. A caregiver must sign an Informed Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form.

• The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, according to the criteria a (above), they must be willing and able to participate in the study. No more than one working male per family may be excluded from evaluation if he is self-assessed as being lice free and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility; otherwise the entire household will be excluded from study participation.

• Subject and/or their caregiver must be physically able and willing to apply the test article.

• Subject agrees not to use any other form of lice treatments (commercial, community-anecdotal, or mechanical/manual) while they are participating in the study.

• Following application and rinsing of Study Treatment, subject agrees not to shampoo, wash, or rinse their hair or scalp until the 24-hour post-treatment evaluation has been completed.

• Subject agrees that they will not cut or chemically treat their hair while they are participating in the study.

• Subject agrees to follow all study instructions.

• Female subjects of childbearing potential (including a female caregiver even if she is not being treated) must be willing to have a urine pregnancy test.

• In the event of a subject judged to be incapable of self-treating, the household must have a caregiver willing to apply the treatment at home.

Exclusion Criteria:

• History of irritation or sensitivity to ivermectin or the cream components, pediculicides or hair care products.

• Presentation at the treatment site with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or sponsor, will interfere with safety and/or efficacy evaluations.

• Presentation at the treatment site with eczema or atopic dermatitis on the skin/scalp.

• Treatment with a marketed pediculicide (Over the counter [OTC] or Prescription) in the last 7 days.

• Any condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol.

• Is receiving any other treatment which, in the opinion of the investigator or study monitor, may interfere with the study results.

• Females (including caregivers who come in contact with the investigational product) who are pregnant, nursing or planning a pregnancy. (NOTE: female caregivers and all enrolled females of childbearing potential must have a negative urine pregnancy test prior to treatment). If a household has a pregnant female who has an active case of lice, the entire household is excluded from participation. If this pregnant household member does not have an active infestation, this individual must NOT be the caregiver (one who provides treatment to other household members).

• Is of child-bearing potential and unwilling to use an adequate method of contraception for the duration of the study. Adequate methods of contraception include: abstinence, vasectomized partner, oral birth control pills, birth control injections or patches, Intra Uterine Devices, condoms with a spermicidal jelly or a diaphragm with spermicidal jelly, surgical sterilization.

• Participation in a previous investigational drug study within the past 30 days.

• Does not understand the requirements for study participation and/or may likely exhibit poor compliance, in the opinion of the investigator.

• Does not have a known household affiliation with their household members (i.e., do not stay in one household consistently, sleeping at one place several nights and then at another place or location). Household is defined as living in a shared area or space (for example the same house or apartment unit).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Head Lice

Intervention

Drug:
• Ivermectin cream
Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
• vehicle control
Up to 4 ounces of vehicle control applied to the hair and scalp on day 1

Locations

Country	Name	City	State
United States	Lovelace Scientific Resources, Inc.	Albuquerque	New Mexico
United States	Haywood Pediatric Adolescent Medicine Group, PA	Clyde	North Carolina
United States	Lice Cleanique, LLC	Delray Beach	Florida
United States	Minnesota Clinical Study Center	Fridley	Minnesota
United States	Northeast Houston Pediatric Clinic	Houston	Texas
United States	Impact Clinical Trials	Los Angeles	California
United States	Hill Top Research Corp.	Miamiville	Ohio
United States	LSRN	Nashville	Tennessee
United States	Virgina Clinical Research, Inc.	Norfolk	Virginia
United States	Hill-Top Research Corp	St Petersburg	Florida
United States	LSRN	West Palm Beach	Florida
United States	Cactus Kids Pediatrics	Yuma	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Topaz Pharmaceuticals Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Treatment Success Following Treatment With Either Ivermectin or Placebo (Vehicle Control)	Treatment success was defined as the absence of live lice and was determined by visual examination of hair and scalp by a trained evaluator.	Days 2 up to Day 15 post-treatment	No
Primary	Number of Participants Reporting Adverse Events Post-Treatment With Either Ivermectin or Placebo (Vehicle Control)		Day 1 up to Day 28 post-application	No
Primary	Summary of the Reported Skin/Scalp Irritations Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)	Participants skin/scalp irritations were assessed before treatment (Day 1) and Post-treatment with either Ivermectin or placebo by a trained evaluator.; Severe scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - Large areas of the scalp are red; Severe Excoriation: Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.	Day 1 up to Day 15 post-application	No